IDAHO FALLS, Idaho, Sept. 4, 2012 /PRNewswire/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) is pleased to announce the U.S. Nuclear Regulatory Commission (NRC) has completed its review, approval, and publication of the final Environmental Impact Statement (EIS) for the Company's planned depleted uranium de-conversion and fluorine extraction processing facility. The final EIS is published as U.S. NRC Regulation (NUREG-2113) and is available on the NRC website. The NRC and Environmental Protection Agency (EPA) have published notices of the final EIS in the Federal Register.

The Company originally submitted its license application to the NRC in December 2009, and the NRC has been reviewing that application since that time. The Company previously announced on May 31, 2012 the NRC had completed its approval and publication of the Safety Evaluation Report (SER) for the planned facility. The NRC approval and the EPA's publication of the final EIS represents approval of the last documents required for the NRC construction and operating license to be issued. The final EIS is required to be posted in the Federal Register for 30 days prior to the NRC's issuance of the license. Based upon the final EIS publication date the Company anticipates that the NRC will be issuing the license to the Company on or about the first week of October 2012.

Steve T. Laflin, President and CEO of the INIS commented, "The NRC approval of the final EIS is the last major milestone in the Company's nearly three year effort to license and construct the first ever "green" depleted uranium de-conversion and fluorine extraction processing facility in the U.S. The conclusion of the final EIS that the facility will have a small environmental impact is indicative of the efforts the Company has made to design the plant using state of the art engineering controls and place a high priority upon environmental considerations intended to reduce the footprint and environmental influence of the facility on the south east New Mexico landscape. I would once again like to recognize the NRC staff for their excellent coordination and communication with the Company throughout the license review process and their efforts to complete the license review process in as timely a manner as possible."

About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's plans to construct the first commercial depleted uranium de-conversion and fluorine extraction processing facility in the U.S. and expectations regarding the NRC issuance of the construction and operating license for the facility. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including our Annual Report on Form 10-K for the year ended December 31, 2011. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

(Date:12/9/2016)... LLC announced today that Steven E. Dawson has been appointed as chief ... Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing and executing transformation, ... brings to the company deep operational and leadership expertise, a strong financial ...

(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... travel vaccines market to grow at a CAGR of 6.83% during ... and the growth prospects of the global travel vaccines market for ... generated from the sales of various vaccines administered to actively immunize ...

(Date:12/8/2016)... 8, 2016 IRIDEX Corporation (NASDAQ: IRIX ... shares of common stock, $0.01 par value (the "Offering" with ... offering. The final terms of the Offering will depend on ... there can be no assurance as to whether or when ... use the net proceeds it will receive from this offering ...